Across TCGA pan-cancer cohorts, MIR514A2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR514A2 data layer compared with 2 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher MIR514A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR514A2 expression acts as an unfavorable survival marker.
ESCA are the cancer types where MIR514A2 Mutation most reproducibly stratifies survival.